1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) / National Cancer Institute (NCI). Supports the transition of advanced, emerging technologies that are poised to significantly improve basic or clinical cancer research toward ultimate validation and wide application.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
Opportunity Listing - Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Simpler. Grants. gov uses Login.
gov to verify your identity and manage your account securely. You don't need a separate username or password for this site. Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Agency: National Institutes of Health 93.
394 -- Cancer Detection and Diagnosis Research Open Open opportunity Last Updated: Jun 3, 2026 View version history on Grants.
gov Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research.
This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary... data, but still require further development and rigorous technical validation to encourage adoption by the research community.
Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases.
Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
For-profit organizations other than small businesses Federally recognized Native American tribal governments Special district governments City or township governments Public and Indian housing authorities Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Independent school districts Public and state institutions of higher education Private institutions of higher education Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Grantor contact information National Cancer Institute (NCI) File name Description Last updated RFA-CA-27-002-Full-Announcement. html RFA-CA-27-002-Full-Announcement.
html Link to additional information Closing: November 10, 2026 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Nonprofits with or without 501(c)(3) IRS status, public/private universities, and research institutions. Confirm the full requirements in the official notice before applying.
The current listing shows up to $5,900,000 total (Minimum $300,000). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) / National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleNIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read article